Treatment of fungal infections in patients infected with the human immunodeficiency virus.
Mycoses due to a variety of organisms have been implicated as opportunistic pathogens in patients infected with HIV. These infections are a cause of significant morbidity and mortality, and most often require life-long antifungal medication to suppress reactivation of the fungal process. With the advent of newer antifungal drugs, such as fluconazole and itraconazole, options are available so that appropriate nontoxic, long-term therapy can be administered. As the number of HIV-infected people increases and their longevity is extended, fungi will continue to pose challenging problems in diagnosis and therapy.
Sugar
A M
AM
Evans Memorial Department of Clinical Research, Boston University Medical Center, Massachusetts.
D002177:Candidiasis / Q000150:complications / Q000188:drug therapy; D003047:Coccidioidomycosis / Q000150:complications / Q000188:drug therapy; D003453:Cryptococcosis / Q000150:complications / Q000188:drug therapy; D015658:HIV Infections / Q000150:complications*; D006660:Histoplasmosis / Q000150:complications / Q000188:drug therapy; D006801:Humans; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*